Biotech Values

[pi]

On POTP P3 trial interim look

<<If interim data is released from the DSMB to the sponsoring company, then the trial is no longer considered fully blinded.>>

Release of interim data from the DSMB is exactly what POTP is seeking to do, if I am interpreting today's PR correctly.

That would be the only way to get some data to hang one's hat on.

And if the results show a positive trend on PFS or overall survival, it will allow financing on better terms to POTP.

As you point out, there will be a statistical penalty for release of interim data from DSMB. A penalty that POTP seems prepared to pay.